Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.
Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.
复制标题
DOI：
10.3892/or.18.4.867
复制
发表时间：
2007-10
期刊：
影响因子：
4.2
通讯作者：
Isamu Hoshino;H. Matsubara;Y. Akutsu;T. Nishimori;Y. Yoneyama;Kentaro Murakami;H. Sakata;K. Matsushita;T. Ochiai
中科院分区：
文献类型：
--
作者：
Isamu Hoshino;H. Matsubara;Y. Akutsu;T. Nishimori;Y. Yoneyama;Kentaro Murakami;H. Sakata;K. Matsushita;T. Ochiai
过氧化物还原酶（Peroxiredoxins，Prdxs）是一类抗氧化酶，也被认为是哺乳动物细胞中过氧化物的清除剂。一些报道表明，Prdx 1的过表达与几种类型的人类癌症的不良预后有关，Prdx 1是一种普遍表达的蛋白质，是过氧化物酶之一。本研究采用免疫组化方法检测Prdx 1在食管鳞癌中的表达水平，探讨Prdx 1的表达与食管鳞癌临床分期的关系。对114例食管癌手术标本进行免疫组化染色。根据以下评分标准评价Prdx 1的细胞质染色：I级，阴性或弱染色; II级，中度染色; III级，强染色。I级Prx 1表达的患者百分比为20%（23/114），44%为II级（50/114），36%为III级（41/114）。Prdx 1阳性表达与乳腺癌的T分期（P<0.0001）、淋巴结转移（P=0.048）和临床分期（P=0.001）呈负相关。此外，与Prdx 1表达较高的肿瘤患者相比，Prdx 1表达降低的肿瘤患者的总生存期较短（P=0.022）。目前，Prdx 1已被证明是一种肿瘤抑制因子。我们的研究结果提供了强有力的证据，Prdx 1表达减少是食管鳞癌进展的一个重要因素，并可作为一个有用的预后指标。
Peroxiredoxins (Prdxs) are a family of antioxidant enzymes that are also known as scavengers of peroxide in mammalian cells. Some reports have shown that the overexpression of Prdx1, which is one of the peroxiredoxins that is a ubiquitously expressed protein, was related to a poor prognosis in several types of human cancers. In this study, we investigated the expression levels of Prdx1 in esophageal squamous cell carcinoma by immunohistochemistry, and the correlation between the Prdx1 expression and the clinical status was elucidated. Immunohistochemical staining was performed in 114 samples which were collected from surgical esophageal cancer specimens. Cytoplasmic staining of Prdx1 was evaluated based on the following scoring criteria: Grade I, negative or weak staining; Grade II, moderate staining; and Grade III, strong staining. The percentage of patients with a Grade I expression of Prx1 was 20% (23 of 114), 44% had Grade II (50 of 114), and 36% had Grade III (41 of 114). The Prdx1 immunoreactivity showed an inverse significant correlation with T-category (P<0.0001), lymph node metastasis (P=0.048), and stage (P=0.001). In addition, the patients with tumors exhibiting a reduced Prdx1 expression had shorter overall survival (P=0.022) in comparison to the patients with tumors which had a higher Prdx1 expression. Currently, Prdx1 has been shown to act as a tumor suppressor. Our results provide strong evidence that the reduced Prdx1 expression is an important factor in esophageal squamous cancer progression and could serve as a useful prognostic marker.